AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.180
-0.010 (-0.84%)
May 13, 2025, 4:00 PM - Market closed
AN2 Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 19.99 | 21.35 | 15.65 | 27.22 | 12.1 | 4.07 | Upgrade
|
| Short-Term Investments | 47.08 | 62.27 | 91.65 | 68.84 | 46.46 | - | Upgrade
|
| Cash & Short-Term Investments | 67.06 | 83.62 | 107.3 | 96.06 | 58.56 | 4.07 | Upgrade
|
| Cash Growth | -41.28% | -22.07% | 11.70% | 64.05% | 1338.70% | -27.30% | Upgrade
|
| Other Receivables | - | 0.3 | 1.4 | - | - | - | Upgrade
|
| Receivables | - | 0.3 | 1.4 | - | - | - | Upgrade
|
| Prepaid Expenses | 2.5 | 2.34 | 1.81 | 2.51 | 1.55 | 0.16 | Upgrade
|
| Other Current Assets | - | - | - | 0.05 | - | - | Upgrade
|
| Total Current Assets | 69.56 | 86.26 | 110.51 | 98.62 | 60.11 | 4.23 | Upgrade
|
| Long-Term Investments | 11.48 | 5.02 | 27.19 | 3.22 | 3.49 | - | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 1.72 | - | Upgrade
|
| Other Long-Term Assets | 0.3 | 0.8 | 1.04 | 0.72 | - | - | Upgrade
|
| Total Assets | 81.34 | 92.09 | 138.74 | 102.56 | 65.32 | 4.23 | Upgrade
|
| Accounts Payable | 3.07 | 3.32 | 2.68 | 2.12 | 1.06 | 0.13 | Upgrade
|
| Accrued Expenses | 4.57 | 6.13 | 10.7 | 5.01 | 2 | 1.31 | Upgrade
|
| Current Portion of Leases | - | - | - | 0.05 | - | - | Upgrade
|
| Other Current Liabilities | 0.37 | 0.79 | 0.67 | 0.01 | 0.33 | 0.01 | Upgrade
|
| Total Current Liabilities | 8.01 | 10.24 | 14.04 | 7.19 | 3.4 | 1.46 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0 | 0.01 | 0.02 | Upgrade
|
| Total Liabilities | 8.01 | 10.24 | 14.04 | 7.19 | 3.41 | 1.48 | Upgrade
|
| Additional Paid-In Capital | 289.71 | 287.59 | 278.88 | 185.47 | - | - | Upgrade
|
| Retained Earnings | -216.43 | -205.78 | -154.46 | -89.72 | -47.38 | -20.32 | Upgrade
|
| Comprehensive Income & Other | 0.05 | 0.03 | 0.28 | -0.37 | -0.03 | - | Upgrade
|
| Total Common Equity | 73.33 | 81.85 | 124.7 | 95.37 | -47.41 | -20.32 | Upgrade
|
| Shareholders' Equity | 73.33 | 81.85 | 124.7 | 95.37 | 61.91 | 2.75 | Upgrade
|
| Total Liabilities & Equity | 81.34 | 92.09 | 138.74 | 102.56 | 65.32 | 4.23 | Upgrade
|
| Total Debt | - | - | - | 0.05 | - | - | Upgrade
|
| Net Cash (Debt) | 67.06 | 83.62 | 107.3 | 96.01 | 58.56 | 4.07 | Upgrade
|
| Net Cash Growth | -41.28% | -22.07% | 11.76% | 63.96% | 1338.70% | -16.43% | Upgrade
|
| Net Cash Per Share | 2.24 | 2.80 | 4.55 | 6.26 | 22.20 | 1.58 | Upgrade
|
| Filing Date Shares Outstanding | 30.18 | 30.1 | 29.77 | 19.4 | 2.73 | 2.71 | Upgrade
|
| Total Common Shares Outstanding | 30.14 | 29.92 | 29.74 | 19.4 | 2.73 | 2.71 | Upgrade
|
| Working Capital | 61.55 | 76.02 | 96.46 | 91.44 | 56.71 | 2.78 | Upgrade
|
| Book Value Per Share | 2.43 | 2.74 | 4.19 | 4.92 | -17.36 | -7.50 | Upgrade
|
| Tangible Book Value | 73.33 | 81.85 | 124.7 | 95.37 | -47.41 | -20.32 | Upgrade
|
| Tangible Book Value Per Share | 2.43 | 2.74 | 4.19 | 4.92 | -17.36 | -7.50 | Upgrade
|
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.